Literature DB >> 2685358

Biosynthesis of hepatitis B virus e antigen: directed mutagenesis of the putative aspartyl protease site.

O Jean-Jean1, S Salhi, D Carlier, C Elie, A M De Recondo, J M Rossignol.   

Abstract

The C gene products of all mammalian hepadnaviruses contain a region with sequence similarities to the catalytic center of the aspartyl proteases. This region could have the capacity to cleave precore proteins, leading to the synthesis of e antigen. By site-directed mutagenesis on a plasmid containing the hepatitis B virus C gene, we have replaced either the Asp residue of the putative aspartyl protease catalytic center or an Asp residue located 3 amino acids upstream. Transient expression of the mutated hepatitis B virus C gene in human and mouse cells showed that none of these mutations prevented the secretion of an accurately processed HBe antigen. Thus, we demonstrated that the aspartyl protease responsible for e antigen precursor processing is not C gene encoded but is more likely to be a cellular enzyme. From these results, we suggest a model for the mechanism of e antigen synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2685358      PMCID: PMC251224     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases.

Authors:  D D Loeb; C A Hutchison; M H Edgell; W G Farmerie; R Swanstrom
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

Review 2.  Prohormone processing and the secretory pathway.

Authors:  J M Fisher; R H Scheller
Journal:  J Biol Chem       Date:  1988-11-15       Impact factor: 5.157

3.  Thermostable DNA polymerase from the archaebacterium Sulfolobus acidocaldarius. Purification, characterization and immunological properties.

Authors:  C Elie; A M De Recondo; P Forterre
Journal:  Eur J Biochem       Date:  1989-01-02

4.  Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus.

Authors:  J Salfeld; E Pfaff; M Noah; H Schaller
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  Biological activity of pepstatins, pepstanone A and partial peptides on pepsin, cathepsin D and renin.

Authors:  T Aoyagi; H Morishima; R Nishizawa; S Kunimoto; T Takeuchi
Journal:  J Antibiot (Tokyo)       Date:  1972-12       Impact factor: 2.649

6.  Specific chemical modifications of acid proteases in the presence and absence of pepstatin.

Authors:  K Takahashi; W J Chang
Journal:  J Biochem       Date:  1973-03       Impact factor: 3.387

7.  Mode of inhibition of acid proteases by pepstatin.

Authors:  J Marciniszyn; J A Hartsuck; J Tang
Journal:  J Biol Chem       Date:  1976-11-25       Impact factor: 5.157

8.  Expression mechanism of the hepatitis B virus (HBV) C gene and biosynthesis of HBe antigen.

Authors:  O Jean-Jean; M Levrero; H Will; M Perricaudet; J M Rossignol
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

9.  Proteaselike sequence in hepatitis B virus core antigen is not required for e antigen generation and may not be part of an aspartic acid-type protease.

Authors:  M Nassal; P R Galle; H Schaller
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

10.  Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation.

Authors:  S F Le Grice; J Mills; J Mous
Journal:  EMBO J       Date:  1988-08       Impact factor: 11.598

View more
  2 in total

1.  Hepatitis B virus p25 precore protein accumulates in Xenopus oocytes as an untranslocated phosphoprotein with an uncleaved signal peptide.

Authors:  S Q Yang; M Walter; D N Standring
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  Biogenesis of hepatitis B virus e antigen is driven by translocon-associated protein complex and regulated by conserved cysteine residues within its signal peptide sequence.

Authors:  Helena Zábranská; Aleš Zábranský; Barbora Lubyová; Jan Hodek; Alena Křenková; Martin Hubálek; Jan Weber; Iva Pichová
Journal:  FEBS J       Date:  2021-12-18       Impact factor: 5.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.